Giant clinically Non-Functioning Pituitary Neuroendocrine Tumor

see also Giant pituitary neuroendocrine tumor.

Forty patients (24 men, age 54.2 ± 16.2 years) were studied. The maximum tumor diameter [median (interquartile range)] was 4.6 cm (4.1-5.1). Women had larger tumors [4.8 cm (4.2-5.4) vs. 4.5 cm (4.0-4.9); p=0.048]. Hypopituitarism [partial (n=22, 55%) or complete (n=9, 22.5%)] at diagnosis was present in 77.5% of the patients. Visual field defects were found in 90.9%. The most used surgical technique was endoscopic endonasal transsphenoidal (EET) surgery (n=31, 77.5%). Radiotherapy was used in 11 (27.5%) patients (median dose 50.4 Gy, range 50-54). Thirty-seven patients were followed for 36 months (10-67 months). Although more than half of these patients showed tumor persistence (n=25, 67.6%), tumor size was significantly reduced [0.8 cm (0-2.5); p<0.001]. At last visit, 12 patients (32.4%) showed absence of tumor on MRI. Hypopituitarism rate was similar (75.0%), although with significant changes (p<0.001) in the distribution of the type of hypopituitarism. The absence of tumor at the last visit was positively associated with positive immunohistochemical staining for FSH (p=0.01) and LH (p=0.006) and negatively with female sex (p=0.011), cavernous sinus invasion (p=0.005) and the presence of Knosp grade 4 (p=0.013).

gNFPAs are more frequent in men but tumors are larger in women. Surgical treatment is followed by a complete tumor resection rate of approximately 30%. Positive immunostaining for gonadotropins is associated with tumor absence at last revision, while female sex and invasion of the cavernous sinuses with tumor persistence ¹⁾.

1: Nihonmatsu A, Nishimura F, Park YS, Motoyama Y, Nakagawa I, Yamada S, Tamura K, Matsuda R, Takeshima Y, Takamura Y, Nakase H. Late-Onset Intractable Cerebrospinal Fluid Leakage After Stereotactic Radiotherapy After Resection of Giant Nonfunctioning pituitary neuroendocrine tumor. World Neurosurg X. 2019 Jun 28;4:100055. doi: 10.1016/j.wnsx.2019.100055. eCollection 2019 Oct. PubMed PMID: 31360918; PubMed Central PMCID: PMC6639739.

2: Zhang R, Wang Z, Gao L, Guo X, Feng C, Deng K, Lian W, Yao Y, Feng M, Bao X, Wang R, Xing B. Clinical Characteristics and Postoperative Recovery of Hypopituitarism in Patients with Nonfunctional pituitary neuroendocrine tumor. World Neurosurg. 2019 Jun;126:e1183-e1189. doi: 10.1016/j.wneu.2019.03.062. Epub 2019 Mar 14. PubMed PMID: 30880207.

3: Batista RL, Trarbach EB, Marques MD, Cescato VA, da Silva GO, Herkenhoff CGB, Cunha-Neto MB, Musolino NR. Nonfunctioning pituitary neuroendocrine tumor Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile. World Neurosurg. 2018 Dec;120:e241-e246. doi: 10.1016/j.wneu.2018.08.043. Epub 2018 Aug 20. PubMed PMID: 30138730.

4: Barzaghi LR, Losa M, Capitanio JF, Albano L, Weber G, Mortini P. Pediatric pituitary neuroendocrine tumors: Early and Long-Term Surgical Outcome in a Series of 85 Consecutive Patients. Neurosurgery. 2019 Jul 1;85(1):65-74. doi: 10.1093/neuros/nyy204. PubMed PMID: 29790934.

5: Zhou WJ, Ma SC, Zhao M, Liu C, Guan XD, Bao ZS, Jia GJ, Jia W. Risk factors and the prognosis of sexual dysfunction in male patients with pituitary neuroendocrine tumors: a multivariate analysis. Asian J Androl. 2018 Jan-Feb;20(1):43-49. doi: 10.4103/aja.aja_18_17. PubMed PMID: 28816201; PubMed Central PMCID: PMC5753553.

6: Nishioka H, Hara T, Nagata Y, Fukuhara N, Yamaguchi-Okada M, Yamada S. Inherent Tumor Characteristics That Limit Effective and Safe Resection of Giant Nonfunctioning pituitary neuroendocrine tumors. World Neurosurg. 2017 Oct;106:645-652. doi: 10.1016/j.wneu.2017.07.043. Epub 2017 Jul 19. PubMed PMID: 28735124.

7: Wang SS, Wei L, Jing JJ, Zhang SM. Three-dimensional reconstruction and morphological characterization of pituitary macroadenomas. Arch Med Sci. 2016 Jun 1;12(3):576-86. doi: 10.5114/aoms.2016.59932. Epub 2016 May 18. PubMed PMID: 27279851; PubMed Central PMCID: PMC4889693.

8: Landeiro JA, Fonseca EO, Monnerat AL, Taboada GF, Cabral GA, Antunes F. Nonfunctioning giant pituitary neuroendocrine tumors: Invasiveness and recurrence. Surg Neurol Int. 2015 Nov 26;6:179. doi: 10.4103/2152-7806.170536. eCollection 2015. PubMed PMID: 26674325; PubMed Central PMCID: PMC4665135.

9: Yildirim AE, Sahinoglu M, Ekici I, Cagil E, Karaoglu D, Celik H, Nacar OA, Belen AD. Nonfunctioning pituitary neuroendocrine tumors Are Really Clinically Nonfunctioning? Clinical and Endocrinological Symptoms and Outcomes with Endoscopic Endonasal Treatment. World Neurosurg. 2016 Jan;85:185-92. doi: 10.1016/j.wneu.2015.08.073. Epub 2015 Sep 4. PubMed PMID: 26344636.

10: Liu J, Li C, Xiao Q, Gan C, Chen X, Sun W, Li X, Xu Y, Chen J, Shu K, Lei T. Comparison of pituitary neuroendocrine tumors in Elderly and Younger Adults: Clinical Characteristics, Surgical Outcomes, and Prognosis. J Am Geriatr Soc. 2015 Sep;63(9):1924-30. doi: 10.1111/jgs.13590. Epub 2015 Aug 27. PubMed PMID: 26313332.

11: Minniti G, Scaringi C, Poggi M, Jaffrain Rea ML, Trillò G, Esposito V, Bozzao A, Enrici MM, Toscano V, Enrici RM. Fractionated stereotactic radiotherapy for large and invasive Non-Functioning Pituitary Neuroendocrine Tumors: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol. 2015 Apr;172(4):433-41. doi: 10.1530/EJE-14-0872. Epub 2015 Jan 27. PubMed PMID: 25627653.

12: Wang F, Zhou T, Wei S, Meng X, Zhang J, Hou Y, Sun G. Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary neuroendocrine tumors. Surg Endosc. 2015 Jun;29(6):1270-80. doi: 10.1007/s00464-014-3815-0. Epub 2014 Oct 1. PubMed PMID: 25270611; PubMed Central PMCID: PMC4422857.

13: Gondim JA, Almeida JP, Albuquerque LA, Gomes EF, Schops M. Giant pituitary adenomas: surgical outcomes of 50 cases operated on by the endonasal endoscopic approach. World Neurosurg. 2014 Jul-Aug;82(1-2):e281-90. doi: 10.1016/j.wneu.2013.08.028. Epub 2013 Aug 29. PubMed PMID: 23994073.

14: Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary neuroendocrine tumor predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013 Apr;34(2):239-77. doi: 10.1210/er.2012-1013. Epub 2013 Jan 31. Review. PubMed PMID: 23371967; PubMed Central PMCID: PMC3610678.

15: Müslüman AM, Cansever T, Yılmaz A, Kanat A, Oba E, Çavuşoğlu H, Sirinoğlu D, Aydın Y. Surgical results of large and giant pituitary neuroendocrine tumors with special consideration of ophthalmologic outcomes. World Neurosurg. 2011 Jul-Aug;76(1-2):141-8; discussion 63-6. doi: 10.1016/j.wneu.2011.02.009. PubMed PMID: 21839965.

16: Baumann F, Schmid C, Bernays RL. Intraoperative magnetic resonance imaging-guided transsphenoidal surgery for giant pituitary neuroendocrine tumors. Neurosurg Rev. 2010 Jan;33(1):83-90. doi: 10.1007/s10143-009-0230-4. Epub 2009 Oct 13. PubMed PMID: 19823884.

17: Shamim MS, Bari ME, Khursheed F, Jooma R, Enam SA. pituitary neuroendocrine tumors: presentations and outcomes in a South Asian country. Can J Neurol Sci. 2008 May;35(2):198-203. PubMed PMID: 18574934.

18: Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M. Surgical treatment of giant pituitary neuroendocrine tumors: strategies and results in a series of 95 consecutive patients. Neurosurgery. 2007 Jun;60(6):993-1002; discussion 1003-4. PubMed PMID: 17538372.

19: Zhang X, Fei Z, Zhang J, Fu L, Zhang Z, Liu W, Chen Y. Management of nonfunctioning pituitary neuroendocrine tumors with suprasellar extensions by transsphenoidal microsurgery. Surg Neurol. 1999 Oct;52(4):380-5. PubMed PMID: 10555844.

20: Verhelst J, Berwaerts J, Abs R, Dua G, Van Den Weyngaert D, Mahler C. Obstructive hydrocephalus as complication of a giant nonfunctioning pituitary adenoma: therapeutical approach. Acta Clin Belg. 1998 Feb;53(1):47-52. PubMed PMID: 9562706.

21: Tanaka R, Kameya T, Kasai K, Kawano N, Yada K. [A case of granulomatous hypophysitis]. No Shinkei Geka. 1992 Dec;20(12):1283-8. Japanese. PubMed PMID: 1484596.